2. Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease Immunology/Inflammation NF-κB
  3. PPAR Reactive Oxygen Species (ROS) Keap1-Nrf2
  4. PIISVYWK

PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

PIISVYWK

PIISVYWK Chemical Structure

CAS No. : 2016043-80-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PIISVYWK Related Antibodies

Top Publications Citing Use of Products

View All PPAR Isoform Specific Products:

View All Isoforms
PPARα PPARβ/δ PPARγ PPAR PPARδ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity[1].

In Vitro

PIISVYWK (10-100 μM; 48 h) is non-cytotoxic to BMMSCs[1].
PIISVYWK (10-100 μM; 7 days) inhibits adipocyte differentiation in BMMSCs by suppressing adipogenic transcription factors and lipogenic enzymes, and enhancing lipolysis, with up to 40.97% inhibition of lipid accumulation at 100 μM[1].
PIISVYWK (10-100 μM; 2 days for Nrf2, 3 days for HO-1) activates the HO-1/Nrf2 signaling pathway in BMMSCs, increasing HO-1 cytoplasmic expression and Nrf2 nuclear expression at 100 μM[1].
PIISVYWK (10-100 μM; 7 days) reduces oxidative stress in BMMSCs during adipogenesis by decreasing ROS generation and increasing antioxidant enzyme activities, with significant effects at 100 μM[1].
PIISVYWK (10-100 μM; 7 days) reduces inflammation in BMMSCs by suppressing pro-inflammatory cytokine production and modulating the MAPK pathway, with significant effects at 100 μM[1].
PIISVYWK (100 μM; 7 days, pre-treated with 5 μM ZnPP for 1 h) exerts anti-adipogenic effects in BMMSCs that are mediated by HO-1, as pre-treatment with ZnPP reverses its inhibitory effects on adipocyte differentiation, transcription factor expression, and lipolysis[1].
PIISVYWK (100 μM; 7 days, pre-treated with 5 μM ZnPP for 1 h) exerts oxidative stress-reducing and anti-inflammatory effects in BMMSCs that are mediated by HO-1, as pre-treatment with ZnPP reverses these effects[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PIISVYWK Related Antibodies

Cell Differentiation Assay[1]

Cell Line: bone marrow-derived mesenchymal stem cells (BMMSCs)
Concentration: 10-100 μM
Incubation Time: 7 days
Result: Inhibited lipid accumulation in BMMSCs in a dose-dependent manner, with up to 40.97% inhibition at 100 μM; suppressed the expression of adipogenic transcription factors PPARγ, SREBP-1, and C/EBPα, alongside adipocyte protein 2 (aP2); increased free glycerol levels in the culture medium; inhibited lipogenic enzymes FAS and LPL; upregulated lipolysis-related p-HSL.

Western Blot Analysis[1]

Cell Line: bone marrow-derived mesenchymal stem cells (BMMSCs)
Concentration: 10-100 μM
Incubation Time: 2 days (Nrf2); 3 days (HO-1)
Result: Elevated HO-1 expression in the cytoplasm of BMMSCs, with significance at 100 μM (P < 0.05); increased Nrf2 expression in the cell nucleus at high concentrations (P < 0.05); induced Nrf2 nuclear translocation as observed via immunostaining.

ELISA Assay[1]

Cell Line: bone marrow-derived mesenchymal stem cells (BMMSCs)
Concentration: 10-100 μM
Incubation Time: 7 days
Result: Significantly reduced the production of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in BMMSCs compared to the control group, with significant effects at higher concentrations (P < 0.01 for 100 μM; P < 0.05 for lower concentrations); modulated the MAPK pathway, with changes in p-ERK, p-P38, and p-JNK expression.
In Vivo

PIISVYWK (1-10 mg/kg; p.o.; daily; 15 weeks) significantly reduces weight gain, fat accumulation, and pro-inflammatory cytokines while activating anti-obesity and antioxidant pathways in HFD-induced obese mice at 10 mg/kg, with moderate effects at 1 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 3 weeks old at acclimation start, 6 weeks old at study initiation, HFD-induced obesity model)[1]
Dosage: 1 mg/kg; 10 mg/kg
Administration: p.o.; daily; 15 weeks
Result: Reduced weight gain to 17.29 g, decreased fat percentage to 45.26%, reduced adipose tissue weight, suppressed adipogenic transcription factors (PPARγ, SREBP-1, C/EBPα) and lipogenic enzymes (LPL, FAS, aP2) in subcutaneous adipose tissue, increased p-HSL and p-AMPK expression in subcutaneous adipose tissue, reduced fasting blood glucose to 146.00 mg/dL, reduced total cholesterol (4.98 mmol/L), LDL (1.00 mmol/L), and triglycerides (1.43 mmol/L), increased HDL (1.49 mmol/L) and free glycerol levels, reduced serum pro-inflammatory cytokines (IL-6: 34.33 pg/mL, IL-1β: 17.00 pg/mL, TNFα: 22.67 pg/mL), increased antioxidant enzyme activities (CAT: 35.4 U/mL, SOD: 165.2 U/mL, GPx: 82.7 U/mL), and activated HO-1 and Nrf2 in subcutaneous adipose tissue at 10 mg/kg; moderately reduced weight gain, fasting blood glucose, LDL, pro-inflammatory cytokines, and increased antioxidant enzyme activities at 1 mg/kg.
Molecular Weight

1005.21

Formula

C51H76N10O11
CAS No.
Sequence

Pro-Ile-Ile-Ser-Val-Tyr-Trp-Lys
Sequence Shortening

PIISVYWK
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PIISVYWK Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PIISVYWK2016043-80-2PPARReactive Oxygen Species (ROS)Keap1-Nrf2Peroxisome proliferator-activated receptorsnuclear factor erythroid 2-related factor 2CCAAT/enhancer-binding protein alphaheme oxygenase-1bone marrow-derived mesenchymal stem cellAMP-activated protein kinaseperoxisome proliferator-activated receptor gammamitogen-activated protein kinase pathwayhormone-sensitive lipasesterol regulatory element-binding protein 1high-fat diet-induced obese miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PIISVYWK
Cat. No.:
HY-P11589
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.